US/UK/Canada

Share

About Us

Q-Med is a rapidly growing and profitable biotechnology and medical device company that develops, produces and markets medical implants. Operations focus on four areas, Esthetics, Orthopedics, Uro-Gynecology, and Cell Therapy and Encapsulation.

Pick a time period -
Tags ( Active)

Interim report January - September 2009

• Group revenues from sales of goods and royalties amounted to 1,016 (936) MSEK. • Earnings per share amounted to 6.38 (0.78) SEK. • Operating income amounted to 676 (100) MSEK. • In April 2009 Q-Med AB and Oceana Therapeutics, LCC., based in the US, entered into global agreements regarding commercialization rights to Deflux® and Solesta™. The agreements gave Q-Med an initial payment of 517 MSEK in total in June, partly as a purchase sum for Q-Med Scandinavia, Inc., the subsidiary that was divested within the framework of the agreements, and partly as payment for Oceana’s share of certain

Q-Med AB: Invitation to conference call regarding interim report January-September, 2009

Time: Friday, October 23, 2009 at 10.30 a.m. CET. To join the conference: Swedish dial in number: +46 8 5052 0114 UK dial in number: +44 207 1620 177 Q-Med participants: Bengt Ågerup, CEO Alexander Kotsinas, CFO Karin Falck, Director Corporate Communications Q-Med AB’s Q3 report will be released 08.00 on October 23, 2009. The slide presentation will be available at www.q-med.com, and Investors/Presentations. A recorded version of the presentation will be available for seven working days on tel: Sweden +46 8 505 203 33 or UK +44 20 7031 4064, access code: 84 83 70. Financial information from

Q-Med trading update for the third quarter of 2009

In order to ensure that shareholders have up to date information, Q-Med has deemed it appropriate to provide an interim trading update for the third quarter of 2009. However, it should be noted that there remains a high degree of uncertainty given the current economic environment. Q-Med’s revenues in July and August 2009 have been lower than in the same period in 2008. If revenue development continues at the same rate for the rest of the quarter, total revenues for the third quarter of 2009 will be approximately 20% lower than the same period in 2008. This has contributed to a lower overall

Q-Med and Smith & Nephew takes DurolaneTM PMA in USA to next stage

Q-Med has together with its global partner Smith & Nephew agreed to the next stage in the approval process for the US launch of DurolaneTM Single Injection, Stabilized Hyaluronic Acid. Representatives from Q-Med AB, Sweden, and Smith & Nephew met August 19th with the FDA’s Orthopaedic and Rehabilitation Devices Advisory Committee to discuss clinical evidence for the use of DurolaneTM in the treatment of knee pain caused by osteoarthritis (“OA”). The FDA Advisory Committee did not recommend DurolaneTM for immediate approval, requesting further information as part of the Premarket Approval (“

Interim report January-June 2009

• Group revenues from sales of goods and royalties amounted to 721 (630) MSEK. • Earnings per share amounted to 5.95 (0.32) SEK. • Operating income amounted to 625 (39) MSEK. • Revenues within the Esthetics product area amounted to 591 (516) MSEK and operating income was 142 (118) MSEK. • Net income after tax amounted to 592 (32) MSEK. April - June • Group revenues from sales of goods and royalties amounted to 382 (341) MSEK during the second quarter and operating income amounted to 571 (29) MSEK. Operating income for the Esthetics product area amounted to 92 (63) MSEK and 498 (-8) MSEK for

Q-Med AB invites to conference call regarding half year report January-June, 2009

Time: Thursday, July 23, 2009 at 11.30 a.m. CET. To join the conference: Swedish dial in number: + 46 (0)8 5052 0114 UK dial in number: +44 (0)207 1620 177 Q-Med participants: Bengt Ågerup, CEO Alexander Kotsinas, CFO Karin Falck, Director Corporate Communications Q-Med AB’s Q2 report will be released approximately 10.30 on July 23, 2009. The slide presentation will be available at www.q-med.com, and Investors/Presentations. A recorded version of the presentation will be available for seven working days on tel: Sweden +46 (0)8 505 203 33 or UK +44 (0)20 7031 4064, access code: 83 99 40.

Q-Med has received 60 MUSD from Oceana Therapeutics LLC

The American anti-trust authority has not expressed any objections to the sale of Q-Med’s American subsidiary, Q-Med Scandinavia, Inc. to Oceana Therapeutics, LCC. This means, amongst other things, that Oceana Therapeutics now has the global rights to market and sell the products Deflux® and Solesta™ and that Q-Med AB has received the first payment of 60 MUSD. Oceana has taken over business operations in the USA and will gradually take over the remaining markets during 2009. The previously described transaction between Q-Med and Oceana will generate an additional payment of 15 MUSD when

Q-Med introduces two new Restylane® products with lidocaine

Q-Med is proud to announce Restylane® Lidocaine and Restylane Perlane™ Lidocaine as the latest additions to the Restylane range. Frown lines, wrinkles around the nose, mouth and between the eyes can be quickly managed with the new products Restylane Lidocaine and Restylane Perlane Lidocaine. Through the addition of 0.3 percent lidocaine the products offer maximum effect with a minimum of discomfort during treatment. Lidocaine is a swift and safe local anaesthetic that is widely used by physicians to numb treatment sites. Since we all experience pain differently, it is a comfort to have the

Annual General Meeting of Q-Med AB (publ)

The Annual General Meeting of Q-Med AB (publ) was held on April 29, 2009 at 3 p.m.DividendThe meeting adopted a resolution that no dividend is to be paid to the shareholders.Board and feesThe meeting adopted a resolution to re-elect the following members of the Board: Bertil Hult, Ulf Mattsson, Anders Milton, Tomas Nicolin, Kristina Persson and Bengt Ågerup for the period up until the end of the next Annual General Meeting. The meeting also re-elected Anders Milton as the Chair of the Board.The meeting also adopted a resolution that Board fees of 1,400,000 SEK in total be paid for

Interim report January-March 2009

January-March• Group revenues from sales of goods and royalties amounted to 339 (289) MSEK.• Earnings per share amounted to 0.42 (0.10) SEK.• Operating income amounted to 54 (10) MSEK.• Revenues within the Esthetics product area amounted to 269 (233) MSEK and operating income was 50 (55) MSEK.• Net income after tax amounted to 42 (10) MSEK.Important events after the end of the period• On April 22 Q-Med announced that Q-Med AB and Oceana Therapeutics, LCC., based in the US, have entered into global agreements regarding commercialization rights to Deflux® and Solesta™. The

Q-Med AB invites to conference call regarding Interim report January-March, 2009

Time:Tuesday, April 28, 2009 at 10.15 a.m. CET.To join the conference:Swedish dial in number: + 46 (0)8 505 201 10UK dial in number: +44 (0)20 7162 0077Q-Med participants:Bengt Ågerup, CEOAlexander Kotsinas, CFOThe press release for Q-Med AB’s Q1 report will be released at08.00 a.m. on April 28, 2009.The slide presentation will be available at www.q-med.com, and Investors/Presentations.A recorded version of the presentation will be available for seven working days ontel: Sweden +46 (0)8 505 203 33 or UK +44 (0)20 7031 4064, access code: 83 26 88.Financial

Annual General Meeting of Q-Med AB (publ)

The Board of Directors of Q-Med AB (publ) has of today published a notice to attend the Annual General Meeting, which will be held on Wednesday April 29 at 3 p.m. onQ-Med’s premises. Entrance from Fyrisvallsgatan 5, Uppsala, Sweden. A notice has been published in Upsala Nya Tidning, Svenska Dagbladet and in Post- och Inrikes Tidningar (Swedish Official Gazette). The complete notice of the Annual General Meeting in English can be found on the corporate web site www.q-med.com, and is also attached.Q-Med AB (publ)The Board

Year-End Report 2008

January - December• Group revenues from sales of goods and royalties amounted to 1,272 (1,318) MSEK.• Earnings per share amounted to 0.34 (3.17*) SEK.• Operating income amounted to 50 (371*) MSEK.• Revenues within the Esthetics product area amounted to 1,037 (1,073) MSEK and operating income was 172 (533*) MSEK.• Income after tax amounted to 33 (315*) MSEK.October - December• Group revenues from sales of goods and royalties amounted to 336 (336) MSEK during the fourth quarter and operating income amounted to -50 (-10) MSEK.• Income after tax amounted to -44 (-14) MSEK during

Q-Med AB invites to year-end report conference call

Time: Friday, February 13, 2009 at 10.00 a.m. CET.To join the conference:Swedish dial in number: + 46 (0)8 505 201 10UK dial in number: +44 (0)20 7162 0077Q-Med participants:Bengt Ågerup, CEOAlexander Kotsinas, CFOMadelene Sandgren, Director Investor Relations and Corporate CommunicationsThe press release for Q-Med AB’s end-year report will be released approximately07.30 on February 13, 2009.The slide presentation will be available at:www.q-med.com/ Investors/PresentationsA recorded version of the presentation will be available for seven working days ontel: Sweden

Extraordinary General Meeting of Q-Med AB (publ)

The Extraordinary General Meeting of Q-Med AB (publ) with regard to the resolution concerning the new Board took place on February 4, 2009 at 3 p.m.The meeting adopted the resolution to re-elect Bertil Hult, Anders Milton and Bengt Ågerup for the period up until the end of the next Annual General Meeting. Ulf Mattson, Tomas Nicolin and Kristina Persson were elected as new members of the Board.The meeting also elected Anders Milton as Chairman of the Board.

Q-Med’s election committee presents its proposal for a new Board

As has been announced previously, Lyftet Holding BV has requested an Extraordinary General Meeting of the shareholders to elect a new Board for Q-Med AB. In this connection the election committee presents the following proposal, for resolution at the Extraordinary General Meeting on February 4. The election committee’s proposal has the support of owners representing just under 70 percent of the total number of shares in the company.The election committee consists of:Robert Wikholm, ChairmanAnders MiltonJan-Erik Erenius, AMF PensionIt is proposed that Bertil Hult, a member of the

Q-Med and Palomar terminates international distribution agreement

Q-Med AB, today announced the termination of its international distribution agreement with Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a leading researcher and developer of light-based systems for cosmetic treatments. The international distribution agreement was originally entered into in January 2008 with the intention that Q-Med would eventually be responsible for the marketing, sale and distribution of Palomar’s professional products for esthetic treatments outside North America.Due to the downturn in the world-wide economic environment, Q-Med’s efforts are being concentrated on

Q-Med has obtained registration approval for Restylane® in China

Q-Med has obtained registration approval for Restylane® in China. An application for sales approval will be submitted shortly and it is estimated that sales of the product will begin at the end of the second quarter in 2009.“There is a large appetite for new things in China and great respect for products from the West. We are therefore very pleased about this registration approval, which means that Restylane® will be the first hyaluronic acid product intended for the cosmetic market in China”, says Bengt Ågerup, Q-Med´s President and CEO.

Extraordinary General Meeting of Q-Med AB (publ)

The Board of Directors of Q-Med AB (publ) has published a notice to attend the Extraordinary General Meeting, which will be held on Wednesday February 4, 2009 at 3 p.m. on Q-Med’s premises. Entrance from Fyrisvallsgatan 5, Uppsala, Sweden. A notice has been published in Upsala Nya Tidning, Svenska Dagbladet and in Post- och Inrikes Tidningar (Swedish Official Gazette). The complete notice of the Extraordinary General Meeting in English can be found on the corporate web site www.q-med.com and is also attached.Q-Med AB (publ)The Board

Lyftet Holding B.V. requests an extra shareholders’ meeting in Q-Med AB

The board of directors in Q-Med AB has received from Lyftet Holding B.V. a request for summoning of an extra shareholders’ meeting for election of a new board of directors, subject to the limitations set out in Q-Med’s articles of association.As soon as a date for a shareholders’ meeting has been settled, January 2, 2009 at the latest, a press release will be distributed and a notice will be published in Svenska Dagbladet, Upsala Nya Tidning and Post- och Inrikes Tidningar (Swedish Official Gazette). Information will also be available on the corporate web site.Queries should be

There are no items matching the current filter
There are no more items matching the current filter
Back to top